Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer-Reference-Cited by-同舟云学术

Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer

Published:2020-12 Issue: Volume:141 Page:199-208
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Peng Xingzhou,Long Xiaoyan,Liu Li,Zeng Liang,Yang Haiyan,Jiang Wenjuan,Liao Dehua,Li Kunyan,Wang Jing,Lizaso Analyn^ORCID,Mao Xinru,Xu Qinqin,Mansfield Aaron S.,Yang Nong,Zhang Yongchang^ORCID

Funder

Hunan Provincial Science and Technology Department

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;Ca - Cancer J Clin,2018

2. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

3. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study;Wu;Ann Oncol,2015

4. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer;Lee;J Thorac Oncol,2013

5. The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma;Truini;Clin Canc Res,2019

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer;Med;2024-08

2. Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review;Journal of Thoracic Oncology;2024-07

3. First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations;JTO Clinical and Research Reports;2024-06

4. RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants;JTO Clinical and Research Reports;2024-02

5. Genomic features of lung cancer patients in Indonesia’s national cancer center;BMC Pulmonary Medicine;2024-01-20